Final Results of the Phase II SAPHIRE Trial of Resminostat (4SC-201) in Patients with Relapsed/Refractory Hodgkin Lymphoma

被引：0

作者：

Walewski, Jan ^{[1
]}

Paszkiewicz-Kozik, Ewa ^{[1
]}

Warszewska, Agnieszka ^{[1
]}

Borsaru, Gabriela ^{[2
]}

Moicean, Andreea ^{[3
]}

Hellmann, Andrzej ^{[4
]}

Mayer, Jiri ^{[5
,6
]}

Hauns, Bernhard ^{[7
]}

Mais, Anna ^{[7
]}

Henning, Stefan W. ^{[7
]}

Hentsch, Bernd ^{[7
]}

机构：

[1] Maria Sklodowska Curie Mem Inst & Oncol Ctr, Warsaw, Poland

[2] Spitalul Clin Coltea, Bucharest, Romania

[3] Ctr Hematol & Bone Marrow Transplantat, Bucharest, Romania

[4] Med Univ Gdansk, Gdansk, Poland

[5] Univ Hosp Brno, Dept Internal Med Hematooncol, Brno, Czech Republic

[6] CEITEC Masaryk Univ, Brno, Czech Republic

[7] 4SC AG, Martinsried, Germany

来源：

BLOOD | 2011年 / 118卷 / 21期

关键词：

D O I：

暂无

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

页码：1149 / 1149

页数：1

共 50 条

[21] Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin's Lymphoma
Younes, Anas
Gopal, Ajay K.
Smith, Scott E.
Ansell, Stephen M.
Rosenblatt, Joseph D.
Savage, Kerry J.
Ramchandren, Radhakrishnan
Bartlett, Nancy L.
Cheson, Bruce D.
de Vos, Sven
Forero-Torres, Andres
Moskowitz, Craig H.
Connors, Joseph M.
Engert, Andreas
Larsen, Emily K.
Kennedy, Dana A.
Sievers, Eric L.
Chen, Robert
JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (18) : 2183 - 2189
[22] Phase II study of PEND chemotherapy in patients with refractory/relapsed Hodgkin lymphoma
Ibrahim, D
Smith, MR
Varterasian, M
Karanes, C
Millenson, M
Yeslow, G
Pemberton, P
Lai, P
Abrams, J
Al-Katib, A
LEUKEMIA & LYMPHOMA, 2004, 45 (10) : 2079 - 2084
[23] Phase II Study of Bendamustine in Relapsed and Refractory Hodgkin Lymphoma
Moskowitz, Alison J.
Hamlin, Paul A., Jr.
Perales, Miguel-Angel
Gerecitano, John
Horwitz, Steven M.
Matasar, Matthew J.
Noy, Ariela
Palomba, Maria Lia
Portlock, Carol S.
Straus, David J.
Graustein, Tricia
Zelenetz, Andrew D.
Moskowitz, Craig H.
JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (04) : 456 - 460
[24] Phase II trial of antibody drug conjugate offers hope for relapsed or refractory or refractory Hodgkin lymphoma
Fricker, Janet
BRITISH JOURNAL OF HOSPITAL MEDICINE, 2011, 72 (01) : 11 - 11
[25] Results of a phase II multicenter trial of single-agent gemcitabine in patients with relapsed or chemotherapy-refractory Hodgkin's lymphoma
Venkatesh, H
Di Bella, N
Flynn, TP
Vellek, MJ
Boehm, KA
Asmar, L
CLINICAL LYMPHOMA, 2004, 5 (02): : 110 - 115
[26] Phase II trial of gemcitabine in patients (pts) with relapsed or chemotherapy-refractory Hodgkin's lymphoma (HL).
Venkatesh, H
Di Bella, NJ
Cuasay, LC
Vellek, M
Mirabel, M
Asmar, L
BLOOD, 2002, 100 (11) : 300B - 300B
[27] Camrelizumab plus gemcitabine and oxaliplatin for relapsed or refractory classical Hodgkin lymphoma: a phase II trial
Liu, Yanfei
Ping, Lingyan
Song, Yuqin
Tang, Yongjing
Zheng, Wen
Liu, Weiping
Ying, Zhitao
Zhang, Chen
Wu, Meng
Feng, Feier
Lin, Ningjing
Tu, Meifeng
Zhu, Jun
Xie, Yan
BMC MEDICINE, 2024, 22 (01)
[28] Camrelizumab plus gemcitabine and oxaliplatin for relapsed or refractory classical Hodgkin lymphoma: a phase II trial
Yanfei Liu
Lingyan Ping
Yuqin Song
Yongjing Tang
Wen Zheng
Weiping Liu
Zhitao Ying
Chen Zhang
Meng Wu
Feier Feng
Ningjing Lin
Meifeng Tu
Jun Zhu
Yan Xie
BMC Medicine, 22
[29] Phase II trial for lenalidomide alone in relapsed/refractory aggressive non-Hodgkin lymphoma
不详
CLINICAL LYMPHOMA & MYELOMA, 2007, 7 (05): : 339 - 339
[30] Dexamethasone, cytarabine and oxaliplatin (DHAX) in relapsed or refractory non-Hodgkin's lymphoma patients: Results of an ongoing phase II trial.
Chau, I
Cunningham, D
Hill, M
Catovsky, D
BLOOD, 2000, 96 (11) : 140A - 140A

← 1 2 3 4 5 →